M42's Healthpoint is the official medical partner for Mubadala Abu Dhabi Open 2025 for second consecutive year
Facility will provide comprehensive medical services to the world's top tennis players participating in the tournament
Healthpoint will operate an interactive booth on-site, where visitors can engage with leading medical experts and learn about the latest advancements in sports medicine
Abu Dhabi, UAE: For the second consecutive year, Healthpoint, part of the M42 group and recognized as a center of excellence in sports medicine and orthopedic care, is the official medical partner of the upcoming Mubadala Abu Dhabi Open presented by the Abu Dhabi Sports Council.
With years of dedication to advancing sports medicine and enhancing athletes' well-being, Healthpoint continues to play a pivotal role in supporting the health and performance of world-class athletes. This partnership highlights Healthpoint's commitment to providing exceptional medical care at the premier WTA 500 event, which will be held from February 1 – 8 at the International Tennis Centre, Zayed Sports City, Abu Dhabi.
The tournament, showcasing top female tennis talent including defending champion Elena Rybakina and fan favorite Daria Kasatkina, will feature many of the world's top ranked players on the Women's Tennis Association (WTA) tour, marking another incredibly strong field. As the official medical partner, Healthpoint will deliver comprehensive medical services to ensure the athletes' peak performance, quick recovery, and overall well-being throughout the competition.
Healthpoint will also host an interactive booth on-site, where visitors can engage with leading medical experts and learn about the latest advancements in sports medicine. Healthpoint's team of highly skilled specialists, including Dr. Sebastian Kunz, Consultant Orthopedic Surgeon, Dr. Shimas Salih, Consultant Physical Medicine & Rehabilitation and Dr. Hind Elamin, General Practitioner, will be overseeing the tournament's Medical Center and First Aid booth, offering personalized care to athletes and attendees alike.
Omar Al Naqbi, Chief Executive Officer at Healthpoint, said, 'Healthpoint believes in the power of sport to enhance the health and well-being of individuals, whether they are elite athletes or those striving for a more active lifestyle. We encourage healthier communities through education, prevention and treatment. We are excited to bring our expertise to the Mubadala Abu Dhabi Open, contribute to the success of this prestigious event, and continue supporting athletes throughout the tournament.'
Nigel Gupta, Mubadala Abu Dhabi Open Tournament Director, said: 'We are delighted Healthpoint will once again serve as the official medical partner of the tournament, utilizing their extensive knowledge and expertise to ensure competitors are fully equipped to perform to their maximum level.
'As a sport, tennis is physically demanding, particularly during a tournament in which players are often required to play every few days, meaning elite-level medical care is pivotal to the overall quality of the event.
'Healthpoint boasts a proven track record in delivering medical care of the highest level, and we are very much looking forward to working in collaboration with them for what we believe will be another fantastic competition.'
About Healthpoint
Healthpoint, part of the M42 group, is a multi-specialty hospital based in Abu Dhabi. The hospital includes a wide range of primary and specialty care services, and five centers of excellence: Obesity Management, Metabolic and Bariatric Surgery Center of Excellence, Dentistry, Endoscopy, Orthopedics & Sports Medicine, Physiotherapy & Rehabilitation.
Focusing on a carefully defined set of medically integrated services and practices, Healthpoint's patient-centered approach is organized around medical conditions over the full cycle of care and delivered in integrated practice units (IPUs).
Committed to elevating patient care to the highest standards, Healthpoint has been recognized by numerous renowned international awarding and accrediting bodies. These include the Commission on Accreditation of Rehabilitation Facilities (CARF International), the Joint Commission International (JCI), the Australian Council on Healthcare Standards International (ACHSI), and the American Surgical Review Corporation (SRC).
About M42
M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.
Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
For media inquiries or interview opportunities, please contact:
Maroun Farah
Tel: +971 55 166 2557
Email: mfarah@webershandwick.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gulf Today
a day ago
- Gulf Today
Raducanu downs Bucsa to lead British trio into 2nd round at Queen's Club as Krejcikova crashes out
Emma Raducanu had a comfortable straight sets win over Spain's Cristina Bucsa and was one of three Britons to reach the second round of the WTA 500 tournament at Queen's Club on Tuesday, while Wimbledon champion Barbora Krejcikova crashed out. Bucsa had won their only previous meeting in the first round of this year's Singapore Open, but this time the Spaniard was no match for the 22-year-old wildcard and Raducanu strolled to a 6-1 6-2 win. 'I'm still trying to find my groove on this surface,' Raducanu said. 'I knew today would be a very difficult match, I lost to Cristina earlier in the year so I was trying to make sure that didn't happen again and fight to get myself into the second round.' Raducanu will now face Rebecca Sramkova after the Slovak caused an upset with a 6-4 6-3 win over Czech seventh seed Krejcikova, who only returned to action last month after a back injury kept her out since November. Top tier women's tennis has returned to Queen's Club for the first time since 1973 and the home crowd had plenty to cheer on day two with Katie Boulter and Heather Watson also winning their first-round matches. 'To have the women back here, it feels very special,' Boulter, current British number one, said. 'It's something I've dreamt of, actually walking out on this court, after the last couple of years coming as a fan watching the men.' Boulter beat Australian qualifier Ajla Tomljanovic 7-6(4) 1-6 6-4 and will face fifth seed Diana Shnaider after the Russian 21-year-old defeated Poland's Magdalena Frech 6-4 6-1. Watson defeated Kazakhstan's Yulia Putintseva 6-4 6-3 to earn a second-round clash with another Kazakh, fourth seed former Wimbledon champion Elena Rybakina. 'Very happy to be through here at Queen's,' Watson said. 'It's such a great event so far, and I'm really enjoying playing here, playing on these courts at this amazing club, and staying at home, sleeping in my own bed.' The other Briton in action, Francesca Jones went down 6-2 6-4 to American McCartney Kessler who will meet top seed Zheng Quinwen. Czech Lehecka opens grass campaign with win in Stuttgart: Rising Czech force Jiri Lehecka began his Wimbledon build-up in impressive fashion with a 6-4 6-4 defeat of Benjamin Bonzi in the opening round of the Stuttgart Open on Monday. The eighth seed, whose last match on grass was in the Wimbledon fourth round in 2023, quickly got up to speed to overpower Bonzi, firing down 13 aces. Lehecka, 23, will face 2023 Stuttgart runner-up Jan-Lennard Struff next after he thumped down 30 aces during a 6-4 6-4 victory over Italy's Matteo Arnaldi, his first win against a top-50 opponent this season. American sixth seed Brandon Nakashima came through a battle against Britain's Jacob Fearnley, winning 4-6 7-6(4) 6-1. Top seed at the ATP 250 event is Alexander Zverev. Action also began at the Libema Open in Den Bosch with two-time runner-up Jordan Thompson beginning another run with a 6-4 6-4 defeat of American Aleksandar Kovacevic. Murray leaves door open to coaching return: Former world number one Andy Murray has left the door open to a coaching return after his short stint with Novak Djokovic ended without a trophy, but the Scot said he did not expect to be working with another player anytime soon. Serb Djokovic appointed Murray ahead of this year's Australian Open and said at the Qatar Open in February they would continue working together for an indefinite period. However, the 24-times Grand Slam champion then endured a woeful run of form and the pair parted ways last month ahead of the French Open. 'I would do it again at some stage. I don't think that will happen immediately,' Murray told the BBC on Monday. 'I wasn't planning on going into coaching as soon as I finished playing but it was a pretty unique opportunity. Reuters
Gulf Today
2 days ago
- Gulf Today
Haddad Maia downs Kvitova on opening day of new Queen's Club Championships
Brazil's Beatriz Haddad Maia came from a set down to beat former Wimbledon champion Petra Kvitova and reach the second round of the new WTA 500 event at Queen's Club on Monday. After a 52-year gap since the last top-tier women's event was held at the London grasscourt club, it was fitting that twice Wimbledon winner Kvitova opened proceedings on a court named after former British Wimbledon champion Andy Murray. After an impressive start on the pristine centre court lawn in front of a sizeable crowd, however, the Czech was unable to hold off her younger opponent who prevailed 2-6 6-4 6-4. Kvitova, who won her titles at the All England Club in 2011 and 2014, made her comeback from a 17-month maternity break in February and gained entry to the tournament via a protected ranking. After holding serve in a marathon fifth game, the 35-year-old surged on to win the opening set and looked on course for only her second victory since returning. The rust was apparent though as world number 23 Haddad Maia worked her way back into the match and claimed the win. After levelling the match she got an early break in the deciding set and that proved decisive as she sealed a clash against American third seed Emma Navarro. 'For sure (Petra) is won of the best players on this surface and it's a privilege to be here,' Haddad Maia said. German qualifier Tatjana Maria also made it through as she beat former US Open runner-up Leylah Fernandez 7-6 6-2. Strycova to replace Pala as Czech Billie Jean King Cup team captain: Two-time Wimbledon doubles champion Barbora Strycova will take over as captain of the Czech Billie Jean King Cup team from Petr Pala, the national tennis federation confirmed on Monday. Pala took the helm in 2008 and led the Czechs to six Fed Cup victories in 2011-2018, leaning on the likes of Kvitova, Lucie Safarova, Karolina Pliskova and Strycova herself. The Czechs have been less impressive since the women's team competition changed to the Billie Jean King Cup in 2020, also because of a generational shift. 'I have realised the girls are younger and younger and I'm not getting any younger with them, it's rather the contrary,' Pala, 49, told Czech media on Monday. Agencies
Zawya
03-06-2025
- Zawya
M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care
Partnership will advance cancer diagnosis, inform treatment decisions, and enable real-time monitoring of disease progression in a more cost-effective and less invasive manner The launch is expected in the latter part of Q2 2025, following the completion of an initial validation study at Cleveland Clinic Abu Dhabi Abu Dhabi, United Arab Emirates: M42, a global health leader powered by technology, continues to pioneer artificial intelligence (AI) and medical and clinical solutions as part of its mission to revolutionize health in the UAE and globally. In a major advancement for precision oncology, M42 announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS (Nasdaq: SOPH) to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of cancers. As part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood draw. This approach does not replace but rather complements routine cancer screenings and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer profile. Over the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the UAE. The new testing program will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the region. Validation studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 2025. Over time, the collaboration will serve as a foundation for broader expansion across the Middle East, excluding Saudi Arabia, delivering world-class precision oncology solutions to a wider population. Albarah El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said: "At M42, we are committed to transforming care through innovation and collaboration. By partnering with AstraZeneca and SOPHiA GENETICS, we are bringing world-class liquid biopsy technologies to the UAE, empowering clinicians to deliver more precise and less invasive cancer care. This collaboration reflects our vision of democratizing health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalized care." Sameh El Fangary, Cluster President GCC, AstraZeneca, shared," At AstraZeneca, we are leading the way in the application of precision medicine. Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimizing patient pathways from detection to therapy.' R oss Muken, President of SOPHiA GENETICS, said: "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalize care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." About M42 M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally. Established in 2022, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.
